Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026

By Reuters News

Agenus Inc AGEN.O:

  • AGENUS REPORTS 72% OF PATIENTS WITH LOCALLY ADVANCED DMMR COLON CANCER HAD NO CANCER REMAINING AT SURGERY FOLLOWING SIX WEEKS OF BOT+BAL IN PHASE 2 NEOASIS STUDY AT ESMO 2026

Further company coverage: AGEN.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk